A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone - Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Accéder directement au contenu
Article Dans Une Revue Leukemia & lymphoma Année : 2017

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone

Domaines

Hématologie
Fichier non déposé

Dates et versions

hal-01655961 , version 1 (05-12-2017)

Identifiants

Citer

Véronique Leblond, Pierre Morel, Marie-Sarah Dilhuidy, Xavier Leleu, Carole Soussain, et al.. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. Leukemia & lymphoma, 2017, 58 (11), pp.2615 - 2623. ⟨10.1080/10428194.2017.1307357⟩. ⟨hal-01655961⟩
189 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More